Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Greasley

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Cardiovascular Diabetology|February 20, 2016
Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defectsHelena U Westergren, Sara Svedlund, Remi A Momo, et al.
Diabetes, Obesity & Metabolism|August 20, 2019
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitorsTatiana Yakovleva, Victor Sokolov, Lulu Chu, et al.
BMJ Open Gastroenterology|November 29, 2023
Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort studyNerissa Hoi Ching Lee, Steven J Kiddle, Shardul Chandankhede, et al.
Clinical and Translational Science|October 5, 2019
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose StudyAndrew Whittaker, Åsa M Kragh, Judith Hartleib-Geschwindner, et al.
Lancet (London, England)|November 6, 2023
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trialHiddo J L Heerspink, Arihiro Kiyosue, David C Wheeler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 8, 2025
Protein profiles and associated biological pathways among different etiologies of chronic kidney disease: new insights from DAPA-CKDMark André de la Rambelje, Iris E Beldhuis, Hiddo J L Heerspink, et al.
Journal of Molecular and Cellular Cardiology|March 27, 2022
Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19George R Abraham, Rhoda E Kuc, Magnus Althage, et al.
Clinical and Translational Science|August 16, 2022
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trialIain B Squire, Anders Gabrielsen, Peter J Greasley, et al.
Bioscience Reports|May 15, 2024
Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissueThomas L Williams, Rhoda E Kuc, Anna L Paterson, et al.
Journal of the American Society of Nephrology : JASN|October 1, 2024
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKDJ David Smeijer, Victor S Wasehuus, Neeraj Dhaun, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Cardiovascular Diabetology|February 20, 2016
Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defectsHelena U Westergren, Sara Svedlund, Remi A Momo, et al.
Diabetes, Obesity & Metabolism|August 20, 2019
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitorsTatiana Yakovleva, Victor Sokolov, Lulu Chu, et al.
BMJ Open Gastroenterology|November 29, 2023
Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort studyNerissa Hoi Ching Lee, Steven J Kiddle, Shardul Chandankhede, et al.
Clinical and Translational Science|October 5, 2019
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose StudyAndrew Whittaker, Åsa M Kragh, Judith Hartleib-Geschwindner, et al.
Lancet (London, England)|November 6, 2023
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trialHiddo J L Heerspink, Arihiro Kiyosue, David C Wheeler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 8, 2025
Protein profiles and associated biological pathways among different etiologies of chronic kidney disease: new insights from DAPA-CKDMark André de la Rambelje, Iris E Beldhuis, Hiddo J L Heerspink, et al.
Journal of Molecular and Cellular Cardiology|March 27, 2022
Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19George R Abraham, Rhoda E Kuc, Magnus Althage, et al.
Clinical and Translational Science|August 16, 2022
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trialIain B Squire, Anders Gabrielsen, Peter J Greasley, et al.
Bioscience Reports|May 15, 2024
Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissueThomas L Williams, Rhoda E Kuc, Anna L Paterson, et al.
Journal of the American Society of Nephrology : JASN|October 1, 2024
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKDJ David Smeijer, Victor S Wasehuus, Neeraj Dhaun, et al.
Pageof 9